Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics

IR Contact


David Burke
Vice President, Investor Relations
917.751.5713
david.burke@sernova.com

Email Alerts Sign-Up

Scroll to Top